Immatics N.v. · NASDAQ:IMTX
Immatics — Investor Presentation (July 2021)
37 slides from Immatics's investor presentation, Jul 15, 2021
Slide 1: Unlocking Immunotherapies for Solid Cancer Patients
© Immatics. Not for further reproduction or distribution. Unlocking Immunotherapies for Solid Cancer Patients Immatics Corporate Presentation, July 2021
Slide 2: Forward-Looking Statements
Forward - Looking Statements 2 This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusive and Immatics nor any of its affiliates nor any of its or their con
Slide 3: Building a leading TCR Therapeutics Company with a Pipeline in Cell Therapies and Bispecifics
Building a leading TCR Therapeutics Company with a Pipeline in Cell Therapies and Bispecifics 3 Highly Differentiated Technologies to Identify True Cancer Targets and the Right TCRs Unlocking Immunotherapies for Solid Cancer Patients Strategic Collaborations with World - leading Industry Players
Slide 4: Limitations of Current Immunotherapies in Solid Cancer Patients
Limitations of Current Immunotherapies in Solid Cancer Patients … Driven by a Lack of Known Cancer - specific Targets 4 1 Chalmers et al. , 2017; 2 SEER Cancer Statistics Review, 1975 - 2017, Estimated New Cancer Cases for 2020 Checkpoint inhibitors mainly effective in tumors with high mutational bu
Slide 5: Accessing Intracellular Cancer Targets with TCR-based Therapeutics
Accessing Intracellular Cancer Targets with TCR - based Therapeutics To Unlock Immunotherapies for Solid Cancer Patients 5 Intro
Slide 6: Immatics' Targeted Approach in Two Distinct Therapeutic Modalities
Immatics’ Targeted Approach in Two Distinct Therapeutic Modalities 6 High tumor burden Lower tumor burden 1 1 Patients at earlier stage of disease, de - bulked tumors, or late - stage patients with reduced tumor burden Specialized Centers All Hospitals & Out - Patient Intro
Slide 7: The Immatics Approach Based on 5 Defined Principles
The Immatics Approach to Disrupt Current Tumor Treatment Paradigms Based on 5 Defined Principles 7 1. True Cancer Targets & Matching Right TCRs 2. Targeted Approach in Two Distinct Modalities: Adoptive Cell Therapy & TCR Bispecifics 3. Optimized Manufacturing to Enhance T cell Persistence & Efficacy
Slide 8: Immatics' Pipeline
Immatics ’ Pipeline 8 Modality Product Candidate Status Preclinical Phase 1a 1 Phase 1b 1 Phase 2 Phase 3 Autologous ACT ACTengine® IMA201 (MAGEA4/8) Proprietary ACTengine® IMA202 (MAGEA1) Proprietary ACTengine ® IMA203 (PRAME) Proprietary ACTengine® IMA204 (COL6A3) Proprietary ACT programs (Undiscl
Slide 9: Pipeline Addresses Significant Number of Cancer Patients
Immatics’ Pipeline Addresses Significant Number of Cancer Patients Prevalence of MAGE4/8, MAGEA1 and PRAME in Major Solid Cancer Indications 9 Niche Indications with Fast Track Development Potential Squamous NSCLC HNSCC ~23,500 HLA - A*02 + cases p.a. Uterine Carcinoma Ovarian Cancer 35% 50% ~23,500
Slide 10: Adoptive Cell Therapy
Adoptive Cell Therapy 10
Slide 11: Key Features of Our Clinical ACTengine Programs
IMA201 IMA202 IMA203 Peptide Target HLA - A*02 - presented peptide derived from MAGEA4/8 MAGEA1 PRAME shown to be naturally and specifically presented on native tumor tissues at d ifferentiated high peptide target density 1 100 - 1,000 copies/cell 50 - 900 copies/cell 100 - 1,000 copies/cell T cell
Slide 12: ACTengine Clinical Programs – Clinical Overview & Patient Flow
ACTengine ® Clinical Programs – Clinical Overview & Patient Flow 12 * Thereof 10 patients evaluable for biological activity and clinical efficacy analysis at data cut - off; * * D ose modifications of lymphodepletion regimen for certain risk groups (e.g. patients with HCC & patients with reduced ren
Slide 13: TEAEs by maximum severity
13 TEAEs by maximum severity ( N=16) Adverse event All Grades ≥ Grade 3 No . % No . % Patients with any adverse event 16 100.0 16 100.0 Lymphopenia 16 100.0 16 100.0 Leukopenia 16 100.0 16 100.0 Neutropenia 16 100.0 15 93.8 Anaemia 16 100.0 10 62.5 Thrombocytopenia 15 93.8 6 37.5 Nausea 11 68.8 0 0
Slide 14: ACTengine Biological Activity: Engraftment, Persistence and Infiltration
ACTengine® Clinical Programs – Biological Activity T cells R obustly Engraft, Persist and Infiltrate into Tumor after Infusion of Low Doses of ACTengine® • Robust T cell engraftment and persistence post infusion until the end of the observation period as assessed by qPCR * • Engineered T cells are d
Slide 15: ACTengine Best Overall Response Assessment
ACTengine® Clinical Programs – Best Overall Response (BOR) Assessment Disease Control in 9 out of 10 Patients at Dose Level 1 and 2 (below 1 Billion Transduced CD8 T cells) IMA201 IMA202 IMA203 Patient 201 - DL1 - 01 202 - DL1 - 01 202 - DL1 - 02 202 - EC1 - 01 202 - DL2 - 01 202 - DL2 - 02 203 - DL
Slide 16: Change of Sum of Diameters in Target Lesions
ACTengine ® Clinical Programs – Change of Sum of Diameters in Target Lesions Tumor Shrinkage Observed in 8 of 10 Patients at Low Dose Levels 16 1 Shortest diameter for nodal lesions; 2 Stable target lesions with parallel growth of a CNS non - target lesion ; 3 RECIST1.1 response at timepoint of maxi
Slide 17: ACTengine IMA204 – Targeting Tumor Stroma
ACTengine ® IMA204 – Targeting Tumor Stroma Complete Tumor Eradication in vitro & in vivo 1 by Affinity - enhanced IMA204 TCR CD8 - independent TCR leads to tumor eradication in all mice treated Control IMA204 TCR D7 D16 D22 D29 1 In vivo data by Jim Riley, University of Pennsylvania, control: non -
Slide 18: Combating Tumor Heterogeneity & Escape through Multi-Target Approach
Combating Tumor Heterogeneity & Escape through Multi - Target Approach A Multi - Step Approach towards Highly Personalized Multi - TCR - T Therapy 18 ACTolog ® ACTengine ® TCR - T Personalized Multi - TCR - T 1 2 3 Combination Trial ACTengine ® Multi - TCR - T 4 >200 prioritized XPRESIDENT® targets
Slide 19: ACTengine IMA200 Series – Summary and Future Directions
ACTengine® IMA200 Series – Summary and Future Directions • IMA201, IMA202, IMA203 clinical trials • Complete Dose Escalation • Initiate Dose Expansion and treat patients at target dose • Update on patients treated at target dose expected for 2H2021 Next Steps 19 Transient and manageable treatment -
Slide 20: ACTallo IMA301 – Towards Off-the-shelf ACT
ACTallo® IMA301 – Towards Off - the - shelf ACT Effective Redirection of γδ T cells Using αβ TCR 20 • Proprietary manufacturing protocol delivering robust expansion of γδ T cells with the potential for hundreds of doses from one single donor leukapheresis • Off - the - shelf cell therapy , applicabl
Slide 21: TCR Bispecifics
ooe@ immatics TCR Bispecifics a
Slide 22: TCER – Immatics' TCR Bispecifics
TCER® – Immatics ’ TCR Bispecifics Off - the - shelf Biologics Linking Immune Cells to Tumor Cells 22 TCER®
Slide 23: TCER – Superior Proprietary TCR Bispecific Format
TCER® – Superior Proprietary TCR Bispecific Format 23 TCER® 1 Based on comparative preclinical testing Maximizing efficacy x Selection of cancer peptide targets with unusually high t arget density (peptide copy number) x Individual maturation TCR CDR regions leading to >1000x enhanced affinity x Sta
Slide 24: TCER IMA401 Targeting MAGEA4/8
TCER® IMA401 Targeting MAGEA4/8 High Specificity, Potency in Animal Models and Favorable Half - life 24 * TCER® Study day - 14: transplantation of tumor cells Study day 1: human PBMC transplantation & start of IMA401 weekly treatment Patient - Derived Tumor Model 2 Preclinical Proof - of - Concept D
Slide 25: TCER IMA401 High Target Density Across Multiple Tumor Indications
TCER® IMA401 Targeting MAGEA4/8 High Target Density Across Multiple Tumor Indications >5 - fold higher target density 1 than a commonly used MAGEA4 target peptide 25 MAGEA4/8 Peptide ( q uantitative mass spectrometry detection) Normal tissue Cancer tissue Status as of Oct 2020 MAGEA4/8 target peptid
Slide 26: TCER IMA402 Targeting PRAME
TCER® IMA402 Targeting PRAME High Specificity and Anti - tumor Activity in vitro and in Mice Studies 26 TCER® Preclinical Proof - of - Concept Data: • High - affinity TCR Candidates after affinity - maturation via yeast display • High potency at low concentrations and physiological target density in
Slide 27: TCER IMA402 PRAME Prevalence Across Tumor Indications
TCER® IMA402 Targeting PRAME High Prevalence and Homogeneity of PRAME across Multiple Tumor Indications 27 Normal tissue Cancer tissue PRAME Peptide detection (MS) SqNSCLC Ovarian Cancer PRAME RNA detection in tumor samples (ISH) Indications Target p revalence [%] Uterine carcinoma 100 Melanoma 95 O
Slide 28: Discovery Platforms
ooe@ immatics Discovery Platforms
Slide 29: XPRESIDENT – Discovery of True Cancer Targets
XPRESIDENT® – Discovery of True Cancer Targets Pool of 200 Targets as Foundation for our Future Pipeline >2,500 cancer & normal tissues a nalyzed by Quantitative, Ultra - Sensitive Mass Spectrometry pHLA Database based on primary tissues >200 prioritized targets Technology 29 200 Prioritized Targets
Slide 30: Development of the Right TCR – XCEPTOR
Development of the Right TCR – XCEPTOR® Unique Cross - Talk between Target and TCR Discovery 30 TCR Bispecifics T cell engaging receptor (TCER®) Affinity - maturated natural TCR variable domains w ith nanomolar affinity and favorable specificity profile XPRESIDENT® - guided similar peptide counterse
Slide 31: Corporate Information & Milestones
Corporate Information & Milestones 31
Slide 32: Robust IP Portfolio
Robust IP Portfolio Immatics’ Patent Estate – Territorial Coverage 32 • >8,000 cancer targets, TCRs and technology protected by • 3,500 applications and patents filed in all major countries and regions • >100 patent families • >1,550 granted patents, thereof >400 granted patents in the US Corporate
Slide 33: Strong, Focused and Highly Integrated Trans-Atlantic Organization
Strong, Focused and Highly Integrated Trans - Atlantic Organization 33 Senior Leadership, Business Development, Clinical Operations, Intellectual Property, Regulatory Affairs, Communications Senior Leadership, Research and Development (Adoptive Cell Therapy), CMC, Clinical Operations, Regulatory Aff
Slide 34: Experienced Global Leadership Team Across Europe and the US
Experienced Global Leadership Team Across Europe and the US 34 Harpreet Singh Chief Executive Officer Co - Founder 20 yrs biotech experience Carsten Reinhardt Chief Development Officer >20 yrs pharma & biotech experience ( Micromet , Roche, Fresenius) Rainer Kramer Chief Business Officer 25 yrs phar
Slide 35: Upcoming R&D Milestones in 2021
Upcoming R&D Milestones in 2021 35 1H 2021 2H 2021 ACTengine ® IMA201, 202, 203: Initial dose escalation read - out IMA201: Additional read - out at dose level 1 IMA204: IND * submission TCER® IMA401: IND * submission IMA202: Additional read - out at dose level 2 and 3 IMA402: Preclinical PoC & star
Slide 36: Immatics Key Take-Aways
Immatics Key Take - Aways 36 • Broadly positioned in TCR therapeutics space with two distinct treatment modalities: ACT & TCR Bispecifics • ACTengine ® (TCR - T) IMA200 Clinical Series • Proprietary cell manufacturing resulting in younger T cells for better engraftment & persistence • First anti - t
Slide 37: Thank you
86 immiatics A DELIVERING THE POWER OF T CELLS TO CANCER PATIENTS a Thank you >< | in | ¥ |